当前位置：
X-MOL 学术
›
BMC Complement. Altern. Med.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Xiao-ai-ping injection adjunct with platinum-based chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis.
BMC Complementary and Alternative Medicine ( IF 4.782 ) Pub Date : 2020-01-13 , DOI: 10.1186/s12906-019-2795-y Fanchao Feng 1, 2 , Jingyi Huang 1 , Zhichao Wang 1 , Jiarui Zhang 3 , Di Han 1 , Qi Wu 4 , Hailang He 1, 2 , Xianmei Zhou 1, 2
BMC Complementary and Alternative Medicine ( IF 4.782 ) Pub Date : 2020-01-13 , DOI: 10.1186/s12906-019-2795-y Fanchao Feng 1, 2 , Jingyi Huang 1 , Zhichao Wang 1 , Jiarui Zhang 3 , Di Han 1 , Qi Wu 4 , Hailang He 1, 2 , Xianmei Zhou 1, 2
Affiliation
BACKGROUND
Xiao-ai-ping injection (XAPI), as patented Chinese medicine, has shown promising outcomes in non-small-cell lung cancer (NSCLC) patients. This meta-analysis investigated the efficacy and safety of XAPI in combination with platinum-based chemotherapy.
METHODS
A comprehensive literature search was conducted to identify relevant studies in Pubmed, EMBASE, the Cochrane Library, Chinese National Knowledge Infrastructure, Wangfang Database, VIP Database, and Chinese Biology Medical Database from the date of their inception to September 2018. The RevMan 5.3 software was applied to calculate the risk ratio (RR) and mean difference (MD) with 95% confidence interval (CI).
RESULTS
We included and analyzed 24 randomized controlled trials. The meta-analysis showed that XAPI adjunctive to platinum-based chemotherapy had better outcomes in objective tumor response rate (ORR) (RR: 1.27, 95% CI, 1.14-1.40); improved Karnofsky performance scores (KPS) (RR: 1.70, 95% CI, 1.48-1.95); reduction in occurrence of grade 3/4 leukopenia (RR: 0.49, 95% CI, 0.38-0.64), anemia (RR: 0.63, 95% CI, 0.46-0.87) and thrombocytopenia (RR: 0.53, 95% CI, 0.38-0.73), nausea and vomiting (RR: 0.57, 95% CI, 0.36-0.90); and enhanced immune function (CD8+ [MD: 4.96, 95% CI, 1.16-8.76] and CD4+/CD8+ [MD: 2.58, 95% CI, 1.69-3.47]). However, it did not increase dysregulated liver and kidney function, diarrhea, constipation, and fatigue. Subgroup analysis of ORR and KPS revealed that dosage, treatment duration, and methodological quality did not affect the outcome significantly.
CONCLUSIONS
Our meta-analyses demonstrated that XAPI in combination with platinum-based chemotherapy had a better tumor response, improved the quality of life, attenuated adverse side effects, and enhanced immune function, which suggests that it might be used for advanced NSCLC. Moreover, low dosage (< 60 ml/d) and long-term treatment of XAPI might be a choice for advanced NSCLC patients.
更新日期：2020-02-12
京公网安备 11010802027423号